Botulinum toxin A topical - Eirion Therapeutics
Alternative Names: Botulinum toxin A topical liniment - Eirion Therapeutics; ET-01 - Eirion TherapeuticsLatest Information Update: 05 Oct 2024
At a glance
- Originator Eirion Therapeutics
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Neuromuscular blocking agents; Neurotransmitter modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Facial wrinkles; Hyperhidrosis
Most Recent Events
- 19 Jul 2021 Eirion Therapeutics initiates a phase II trial in Facial wrinkles in USA (Topical) (NCT04985916)
- 15 Mar 2021 Phase-II clinical trials in Hyperhidrosis (Topical) (Eirion Therapeutics pipeline, March 2021)
- 09 Mar 2021 Botulinum toxin A topical licensed to Shanghai Haohai Biological Technology in China